SEARCH

SEARCH BY CITATION

References

  • 1
    Second Thromboembolic Risk Factors (THRiFT II) Consensus group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998; 13: 8797.
  • 2
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell W, Ray JG. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338400.
  • 3
    Weitz JI. Low-molecular weight heparins. N Engl J Med 1997; 337: 68898.
  • 4
    Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert JM, Van Boeckel CAA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents – the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 3752.
  • 5
    Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 3340.
  • 6
    The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695702.
  • 7
    Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, for the ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 237481.
  • 8
    The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 146476.
  • 9
    Turpie AGG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M. Bay 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 247986.
  • 10
    Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 13444.
  • 11
    Kälebo P, Ekman S, Lindbratt S, Eriksson BI, Pauli U, Zachrisson BE, Close P. Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessment. Thromb Haemost 1996; 76: 8936.
  • 12
    Kälebo P, Anthmyr B-A, Eriksson BI, Zachrisson BE. Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials. Acta Radiol 1997; 38: 3206.
  • 13
    Casella G. Refining binomial confidence intervals. Can J Stat 1986; 14: 11329.
  • 14
    Editorial. Ximelagatran: an eulogy. Thromb Res 2006; 118: 3014.
  • 15
    Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001; 21: 10813.
  • 16
    Eriksson BI, Dahl OE, Büller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kälebo P, Reilly P, for the BISTRO II Study Group, A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 17
    Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bösch P, Bauer M, Ekman S, Bach D, Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 132935.